Updated:
Bioverativ Inc.
Bioverativ Inc. — a Waltham biopharma company spun out of Biogen in 2017, focused on hemophilia therapies, acquired by Sanofi for $11.6 billion in 2018.
Bioverativ Inc.
Bioverativ Inc. was established in 2017 as a spinout from Biogen, concentrating on hemophilia treatments and blood disorder therapeutics. The company specialized in recombinant factor replacement therapies for patients with hemophilia A and B, commercializing Eloctate and Alprolix, which had been developed by Biogen. Bioverativ's strategy centered on extending its hemophilia leadership while expanding into sickle cell disease and other rare blood disorders. The company invested in pipeline candidates including BIVV001, a longer-lasting factor VIII therapy, and partnered with Sangamo Therapeutics on gene-editing approaches for hemoglobinopathies. At the time of its acquisition, Bioverativ employed roughly 750 people primarily in the Boston area. The company operated as an independent public entity for just over a year before Sanofi's acquisition closed in March 2018 for $11.6 billion in cash (per Sanofi press release, 2018). Bioverativ's structural distinction was its rapid transition from a Biogen spinout to an acquisition target, demonstrating the strategic value of orphan-drug platforms in the pharmaceutical sector. The company had no separate family-office or charitable structures; its remaining legacy is as a wholly owned subsidiary of Sanofi.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Sector focus
Frequently asked questions
Why was Bioverativ spun out from Biogen?
Biogen spun out Bioverativ in 2017 to separate its hemophilia franchise from its core neurology focus, allowing each company to allocate resources more efficiently (per Biogen investor materials, 2016). The spinout gave Bioverativ its own publicly traded stock and management team.
What were Bioverativ's key commercial products?
Bioverativ's main products were Eloctate (efmoroctocog alfa) for hemophilia A and Alprolix (eftrenonacog alfa) for hemophilia B. Both were long-acting recombinant factor replacement therapies originally developed by Biogen.
Who acquired Bioverativ and for how much?
Sanofi acquired Bioverativ in a cash transaction valued at $11.6 billion, or $105 per share, announced in January 2018 and closed in March 2018 (per Sanofi press release, January 2018).
Is Bioverativ still an independent company?
No. Bioverativ ceased to exist as an independent public company after its acquisition by Sanofi in 2018. The company now operates as part of Sanofi's rare disease division.
What therapeutic areas did Bioverativ target beyond hemophilia?
Bioverativ was developing therapies for sickle cell disease and beta-thalassemia, including a partnership with Sangamo Therapeutics on gene-editing approaches. Its pipeline also included BIVV001, a next-generation factor VIII therapy (per public SEC filings, 2017).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: